Evidence map›Paper›PMID 33271328›Full record

ArticleNeurobiology of disease2021

Neuroprotective effects of a dendrimer-based glutamate carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury.

O Arteaga Cabeza, Z Zhang, E Smith Khoury, R A Sheldon, A Sharma, F Zhang, B S Slusher, R M Kannan, S Kannan, D M Ferriero

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Inhibition of microglial glutaminase alleviates chronic stress-induced neurobehavioral and cognitive deficits.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  6. Dendrimers: Patents for Alzheimer's Disease.Recent patents on nanotechnology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Dynamic Network Connectivity: from monkeys to humans.Frontiers in human neuroscience · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

O Arteaga CabezaDepartments of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA.
Z ZhangDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
E Smith KhouryDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
R A SheldonDepartments of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA; Departments of Newborn Brain Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
A SharmaCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
F ZhangCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
B S SlusherDepartment of Neurology, Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
R M KannanCenter for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
S KannanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: skannan3@jhmi.edu.
D M FerrieroDepartments of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA; Departments of Neurology, University of California San Francisco, San Francisco, CA 94158, USA; Departments of Newborn Brain Research Institute, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: donna.ferriero@ucsf.edu.
Johns Hopkins Medicine · USUniversity of California, San Francisco · USJohns Hopkins University · US

Funding

Precision Therapy for Neonatal Brain InjuryR35NS097299 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIERO, DONNA M. · 2017 to 2024
$6.3M
Targeting glutamate carboxypeptidase in perinatal brain injuryR01NS093416 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Sujatha Kannan, Kannan Rangaramanujam · 2016 to 2026
$4.8M
Development of GCPII inhibitors for the treatment of age-related cognitive disordersR01AG068130 · NIA · JOHNS HOPKINS UNIVERSITY · PI ARNSTEN, AMY F.T., SLUSHER, BARBARA STAUCH · 2020 to 2024
$3.8M
Postnatal combination therapy for cerebral palsyR01HD076901 · NICHD · JOHNS HOPKINS UNIVERSITY · PI RANGARAMANUJAM, KANNAN · 2014 to 2018
$1.7M
NIA NIH HHS R01 AG068130NICHD NIH HHS R01 HD076901NINDS NIH HHS R01 NS093416NINDS NIH HHS R35 NS097299
6 · The paper itself

Abstract

The result of a deprivation of oxygen and glucose to the brain, hypoxic-ischemic encephalopathy (HIE), remains the most common cause of death and disability in human neonates globally and is mediated by glutamate toxicity and inflammation. We have previously shown that the enzyme glutamate carboxypeptidase (GCPII) is overexpressed in activated microglia in the presence of inflammation in fetal/newborn rabbit brain. We assessed the therapeutic utility of a GCPII enzyme inhibitor called 2-(3-Mercaptopropyl) pentanedioic acid (2MPPA) attached to a dendrimer (D-2MPPA), in order to target activated microglia in an experimental neonatal hypoxia-ischemia (HI) model using superoxide dismutase transgenic (SOD) mice that are often more injured after hypoxia-ischemia than wildtype animals. SOD overexpressing and wild type (WT) mice underwent permanent ligation of the left common carotid artery followed by 50 min of asphyxiation (10% O

Indexed as

Neuroprotective AgentsAnimalsAnimals, NewbornBrainDendrimersEnzyme InhibitorsGlutamate Carboxypeptidase IIGlutaratesHypoxia-Ischemia, BrainMiceMice, TransgenicMicrogliaSulfhydryl CompoundsSuperoxide Dismutase-12-(3-mercaptopropyl)pentanedioic acidDendrimersEnzyme InhibitorsGlutamate Carboxypeptidase IIGlutaratesNeuroprotective AgentsSOD1 protein, humanSulfhydryl CompoundsSuperoxide Dismutase-1DendrimerGlutamate carboxypeptidaseMicrogliaN-acetyl-aspartyl-glutamate (NAAG)NanoparticleNeonatal brain injuryNeuroprotection

Identifiers

PMID33271328
PMCPMC8351403
OpenAlexW3108539410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.